Cardiomyopathy
MONDO:0004994A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.
Also known as: Cardiomyopathies, cardiomyopathy
926 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New antibody could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 125 people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove those protein deposits. The goal is to see if it helps people live …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Vertex tests long-term safety of VX-670 for muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug shows promise in reversing lung damage from severe asthma
Disease control OngoingThis study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week che…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for rare bleeding disorder: coagadex trial targets AL amyloidosis
Disease control TerminatedThis phase 3 study tests Coagadex, a human clotting factor X, in 15 adults with acquired factor X deficiency caused by AL amyloidosis. The goal is to see if it safely stops active bleeding and helps manage bleeding during surgery. Participants receive the drug on demand for bleed…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New heart drug aficamten shows promise for japanese patients with thick heart muscle
Disease control OngoingThis phase 3 trial is testing a drug called aficamten in 36 Japanese adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and makes it hard to pump blood. The drug aims to reduce over-contraction of the heart muscle. Researc…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can early enzyme therapy help babies with pompe disease breathe on their own?
Disease control OngoingThis study follows 16 infants aged 6 months or younger with infantile-onset Pompe disease, a rare genetic disorder that weakens muscles and breathing. All receive alglucosidase alfa (Myozyme) as part of their routine care. Researchers track how many survive without needing a brea…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug aims to clear amyloid clumps and save hearts
Disease control OngoingThis phase 3 trial tests whether CAEL-101, an antibody that removes abnormal protein deposits from organs, can help people with AL amyloidosis live longer and avoid heart-related hospital stays. About 281 participants who have not yet received treatment for their plasma cell diso…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Hope for pompe patients: could a switch in enzyme therapy slow decline?
Disease control OngoingThis study tests whether switching to avalglucosidase alfa is safe and more effective for people with late-onset Pompe disease whose condition has worsened on the standard treatment, alglucosidase alfa. Participants receive biweekly infusions of the new drug and are monitored for…
Phase: PHASE4 • Sponsor: Iris Plug • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Weekly shot could replace daily needles for kids with growth disorders
Disease control OngoingThis study tests if a new growth hormone medicine (somapacitan) given once a week works as well as the standard daily growth hormone (Norditropin) for children who are very short due to being born small, or having Turner syndrome, Noonan syndrome, or unknown causes. About 412 chi…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Could a pill replace infusions for gaucher brain symptoms?
Disease control OngoingThis phase 2 trial tests an oral drug called venglustat, given alongside the standard enzyme therapy Cerezyme, in adults with Gaucher disease type 3 (a rare genetic disorder affecting the body and brain). The study has four parts: first, it checks spinal fluid biomarkers to disti…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Gene therapy trial hopes to treat rare muscle disease
Disease control OngoingThis early-stage study tests a gene therapy called AT845 for adults with late-onset Pompe disease, a condition that weakens muscles. The treatment aims to deliver a working copy of the GAA gene to muscle cells. Eleven participants who have been on standard enzyme replacement ther…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail targets Hard-to-Treat amyloidosis
Disease control OngoingThis early-stage trial tests a combination of three drugs—venetoclax, ixazomib, and dexamethasone—in 24 patients with light chain amyloidosis that has returned or not responded to prior treatment. The study focuses on finding the safest dose and checking side effects. All partici…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for rare heart condition in chinese patients
Disease control OngoingThis study tests a drug called eplontersen in Chinese adults with a heart condition caused by abnormal protein buildup. The goal is to see if the drug lowers that protein and is safe over time. Participants will be randomly assigned to receive the drug or a placebo for 24 weeks, …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a drug stop amyloid damage after a heart transplant?
Disease control OngoingThis study tests whether the drug tafamidis can safely stop the progression of ATTR amyloidosis in people who have already received a heart transplant. About 25 stable patients will take tafamidis daily for 12 months. Researchers will measure changes in blood protein levels, nerv…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to tame rare heart disease
Disease control OngoingThis phase 2 trial tests a drug combination including daratumumab for people with AL amyloidosis, a rare disease where abnormal proteins damage organs, especially the heart. The study has two groups: one gets the full combo right away, the other starts some drugs later. Researche…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New device aims to restore heart function in failing hearts
Disease control TerminatedThis study tests a device called AccuCinch that is placed around the heart to help it pump more effectively. It is for people with heart failure and a weakened heart muscle. The goal is to see if the device improves quality of life, exercise ability, and reduces serious heart eve…
Phase: NA • Sponsor: Ancora Heart, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New heart device aims to stop deadly rhythms in heart failure patients
Disease control OngoingThis study tests a new device that combines two heart therapies: one to strengthen heartbeats and another to stop dangerous rhythms. About 300 adults with heart failure and a weak heart pump will get the device. Researchers will check if it safely converts life-threatening heart …
Phase: NA • Sponsor: Impulse Dynamics • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New weekly shot could help severely obese heart patients shed pounds
Disease control OngoingThis Phase 3 study tests a weekly injection called retatrutide in about 1,946 people with severe obesity (BMI ≥35) and established heart disease. The goal is to see if it helps with weight loss and improves heart-related health measures over 113 weeks compared to a placebo. Parti…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a weekly shot slash heart attack risk? major trial underway
Disease control OngoingThis study tests whether a weekly injection of CagriSema (a combination of two drugs) can reduce the risk of heart attacks, strokes, and other heart-related events in people with established cardiovascular disease. About 7,100 participants will receive either CagriSema or a place…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill may replace chemo for kids with brain tumors
Disease control OngoingThis study tests a new drug called DAY101 (tovorafenib) against standard chemotherapy for children and young adults with a type of brain tumor called low-grade glioma that has a specific gene change (RAF alteration). The goal is to see if the new drug works better at shrinking tu…
Phase: PHASE3 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New heart pacing strategy could cut defibrillator need
Disease control OngoingThis study tests whether a special heart pacing technique (left bundle branch pacing) combined with standard heart failure drugs can improve heart function better than drugs alone. It includes 50 adults with non-ischemic heart failure and a specific heart block. The main goal is …
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Asthma breakthrough? new study tests cutting back on meds with benralizumab
Disease control OngoingThis Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can removing blood before heart surgery cut transfusions? large trial aims to find out.
Disease control OngoingThis study tests a technique called acute normovolemic hemodilution (ANH) in 2000 high-risk heart surgery patients. Before the heart-lung machine is used, doctors remove some blood and replace it with fluids. The goal is to see if this reduces the number of patients who need a bl…
Phase: NA • Sponsor: Università Vita-Salute San Raffaele • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for amyloidosis patients: Long-Term safety study of AT-02 underway
Disease control OngoingThis study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the b…
Phase: PHASE2 • Sponsor: Attralus, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to cut heart attacks in High-Risk patients
Disease control OngoingThis phase 3 trial tests whether a monthly injection of pelacarsen can reduce major heart problems like heart attacks and strokes in people with high levels of Lp(a), a genetic risk factor. Over 8,000 participants with existing heart disease are being followed for several years. …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody therapy targets Hard-to-Treat AL amyloidosis
Disease control TerminatedThis trial aimed to test an experimental drug called CM-336 for people with AL amyloidosis that has returned, not responded to treatment, or only partially responded after initial therapy. The drug works by helping the immune system attack and destroy harmful cells. However, the …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New heart drug mavacamten tested in indian patients
Disease control OngoingThis study tests the drug mavacamten in 50 adults in India who have a condition where the heart muscle is too thick and blocks blood flow, causing symptoms like shortness of breath and chest pain. The goal is to see if the drug is safe and works well. Participants will take the d…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for DM1: Long-Term trial of AOC 1001 underway
Disease control ENROLLING_BY_INVITATIONThis phase 3 study is testing the long-term safety and effectiveness of an experimental drug called AOC 1001 (del-desiran) for people with myotonic dystrophy type 1 (DM1), a genetic muscle disorder. The trial enrolls 230 adults who have completed a prior AOC 1001 study and will r…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug eplontersen tested for Long-Term safety in heart disease patients
Disease control ENROLLING_BY_INVITATIONThis study is checking the long-term safety of a drug called eplontersen in people with ATTR-CM, a heart condition caused by abnormal protein buildup. About 1400 adults who completed earlier studies will receive eplontersen injections. Researchers will monitor side effects, kidne…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New enzyme therapy gives hope to babies with rare muscle disease
Disease control OngoingThis study tests a new enzyme replacement therapy called avalglucosidase alfa in babies with infantile-onset Pompe disease, a rare genetic disorder that causes severe muscle weakness and breathing problems. The treatment is given through an IV every other week for up to 4 years. …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could your own stem cells repair a failing heart?
Disease control OngoingThis phase 2 trial is testing whether a patient's own bone marrow stem cells can improve heart function and ease symptoms in people with dilated cardiomyopathy and heart failure. Twenty participants will have stem cells collected from their hip and then infused into their heart a…
Phase: PHASE2 • Sponsor: Barts & The London NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug aims to tame rare blood disorder flares
Disease control OngoingThis Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either ben…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
10-Year study tracks heart drug vyndamax in Real-World patients
Disease control OngoingThis study is monitoring 110 adults in Korea who are taking Vyndamax (tafamidis) for a rare heart condition called ATTR-CM. The goal is to track side effects and see how well the drug works over 10 years in everyday medical practice. Researchers will check heart function and symp…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can tighter blood pressure control save hearts in diabetes? massive trial aims to find out
Disease control OngoingThis large study is testing whether a lower blood pressure target can reduce major heart problems like heart attacks, strokes, and heart failure in people with type 2 diabetes. About 9,500 participants with high blood pressure and high cardiovascular risk are being randomly assig…
Phase: NA • Sponsor: Hospital Israelita Albert Einstein • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could freezing dangerous heart plaque stop a heart attack?
Disease control OngoingThis early study tests a new freezing treatment for people who recently had a heart attack or unstable chest pain. The treatment uses a special balloon to freeze high-risk plaque in the heart's arteries that could rupture and cause another heart attack. The goal is to stabilize t…
Phase: NA • Sponsor: Cryotherapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to find safe doses and check for side effects. About 90 participants will take pa…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to help kids with rare genetic short stature grow taller
Disease control OngoingThis study tests a drug called vosoritide in 56 children with short stature caused by certain genetic conditions. The drug targets the growth plate to help children grow faster. Participants are observed for 6 months, then treated with daily injections for 12 months to check safe…
Phase: PHASE2 • Sponsor: Andrew Dauber • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Heart rhythm showdown: ablation may beat drugs for ventricular tachycardia
Disease control OngoingThis trial tests whether a procedure called catheter ablation works better than anti-arrhythmic drugs for people with structural heart disease who have had a dangerous fast heart rhythm (ventricular tachycardia). About 162 participants will be randomly assigned to either ablation…
Phase: NA • Sponsor: Western Sydney Local Health District • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
One-Time gene therapy aims to halt rare muscle disease
Disease control OngoingThis study tests a single dose of SRP-9003 gene therapy in 17 people with limb girdle muscular dystrophy 2E/R4, a genetic muscle-weakening disease. The goal is to restore a missing protein in muscle cells and improve muscle function. Both walkers and non-walkers can join, and the…
Phase: PHASE3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Desperate hope: gene therapy tested in one patient with rare blindness
Disease control NO_LONGER_AVAILABLEThis expanded access program gave a single patient with Leber Hereditary Optic Neuropathy (a genetic cause of vision loss) an experimental gene therapy called GS010. The treatment was injected into both eyes to test safety. Only one person was involved, so the results are very li…
Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New heart drug EDG-7500 enters Mid-Stage trial for thick heart muscle
Disease control OngoingThis study tests a new drug called EDG-7500 in 100 adults with hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal is to check the drug's safety and how it affects heart function. Participants receive single or multiple doses, and researc…
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for AL amyloidosis patients who failed first-line therapy
Disease control OngoingThis study tests whether adding daratumumab back to pomalidomide and dexamethasone can improve complete remission rates in 15 adults with relapsed or refractory AL amyloidosis who have already received daratumumab. Participants receive the three-drug combination to control the di…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New antibody aims to strip away Heart-Clogging protein in fatal heart disease
Disease control OngoingThis Phase 3 trial tests an experimental drug called ALXN2220 in about 1,180 adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal protein builds up in the heart, causing heart failure. The drug is designed to remove those protein deposits. Partic…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Vutrisiran shows promise for Long-Term control of rare heart condition
Disease control ENROLLING_BY_INVITATIONThis study is for people with a rare heart condition called ATTR amyloidosis with cardiomyopathy, where abnormal protein builds up in the heart. It tests the long-term safety and effectiveness of a drug called vutrisiran, given as an injection every three months. About 700 adults…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental heart drug pulled before first patient enrolled
Disease control TerminatedThis study aimed to test a monthly injection called ION-682884 in people with TTR amyloid cardiomyopathy, a condition where abnormal protein deposits damage the heart. Only patients who had already completed a 2-year study of a similar drug (inotersen) were eligible. The goal was…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental gene therapy targets rare muscle disease in first human test
Disease control OngoingThis early-phase trial tests a single-dose gene therapy called SRP-9003 in 6 people with limb girdle muscular dystrophy type 2E/R4, a rare genetic muscle-weakening disease. The main goals are to check safety and see if the therapy can produce the missing beta-sarcoglycan protein …
Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New antibody combo aims to tame rare blood disease
Disease control OngoingThis early-phase trial tests whether adding the drug isatuximab to standard chemotherapy can safely treat people with high-risk AL amyloidosis, a rare disease where abnormal proteins damage organs. Eleven participants will receive the combination to see if it reduces toxicity and…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene therapy aims to restore sight in rare blindness condition
Disease control OngoingThis phase 3 trial tests a gene therapy called NR082 for Leber's hereditary optic neuropathy (LHON), a genetic condition that causes rapid vision loss. About 95 people aged 12 to 75 with a specific ND4 mutation will receive a single injection of the therapy or a sham procedure. T…
Phase: PHASE3 • Sponsor: Wuhan Neurophth Biotechnology Limited Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Gene therapy shot aims to fix gaucher disease in kids
Disease control OngoingThis early-phase trial tests a single intravenous dose of LY-M001 gene therapy in 9 children (ages 6 to 17) with type 1 Gaucher disease. The goal is to see if it is safe and can improve key symptoms like liver size and blood markers. Researchers will monitor participants for side…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for kids with pompe disease: experimental drug shows promise
Disease control OngoingThis phase 2 trial tests a new enzyme replacement therapy called avalglucosidase alfa (Nexviazyme) in 22 children with infantile-onset Pompe disease who are not responding well to standard treatment. The study aims to see if the new drug is safe and can improve outcomes. Particip…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy hope for kids with rare muscle-wasting disease
Disease control OngoingThis early-stage trial tests a single intravenous dose of a gene therapy (ATA-200) in 4 children aged 6-12 with limb-girdle muscular dystrophy type 2C/R5 (LGMD2C), a rare genetic muscle-weakening condition. The goal is to see if the treatment is safe and tolerable by delivering a…
Phase: PHASE1 • Sponsor: Atamyo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control OngoingThis phase 3 trial tests an experimental drug called AOC 1001 in 159 adults with myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. Participants receive either the drug or a placebo by intravenous infusion. The main goal is to see if the dru…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Heart drug aficamten tested for Long-Term safety in 900 patients
Disease control ENROLLING_BY_INVITATIONThis study follows 900 people with hypertrophic cardiomyopathy who have already taken aficamten in earlier trials. Researchers want to see if the drug is safe and tolerable over a longer period. Participants take aficamten tablets daily, with regular clinic visits to monitor for …
Phase: PHASE2, PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Hope for rare heart disease: new drug aims to slow deadly protein clumps
Disease control OngoingThis study tests a drug called vutrisiran in 655 adults with a rare heart condition caused by abnormal protein buildup (ATTR amyloidosis with cardiomyopathy). The drug is given as a shot every 3 months and aims to reduce deaths and heart-related hospital stays. The goal is to see…
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Gut bacteria capsules may shield heart surgery patients from organ damage
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving patients capsules containing gut bacteria (called Probacine) before and after heart surgery can reduce gut injury and organ failure. Researchers will enroll 500 adults undergoing cardiovascular surgery. The goal is to see if changing the gut microb…
Phase: NA • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Gene therapy trial aims to repair hearts in rare neurological disease
Disease control OngoingThis early-stage trial tests a gene therapy called LX2006 in 8 people with Friedreich's ataxia who also have heart muscle disease. The therapy delivers a healthy copy of the FXN gene to heart cells using a modified virus. The main goal is to check safety over 5 years, while also …
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a gout drug tame high blood pressure?
Disease control OngoingThis study tests whether colchicine, a drug used for gout, can improve blood vessel stiffness and heart function in people with high blood pressure. About 150 adults with hypertension and additional risks like diabetes or high cholesterol will take colchicine or a placebo daily f…
Phase: PHASE2 • Sponsor: Herlev and Gentofte Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug could help teens with rare heart disease
Disease control OngoingThis study tests a drug called mavacamten in 44 teenagers aged 12 to 18 who have a condition where the heart muscle is too thick and blocks blood flow. The goal is to see if the drug can reduce the blockage and improve symptoms. Participants are randomly assigned to receive eithe…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Second dose of experimental drug may help heart amyloidosis patients
Disease control OngoingThis study tests whether a second round of treatment with ALXN2220 is safe and can improve heart function in people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. About 35 adults who previously received the drug will get it a…
Phase: PHASE2 • Sponsor: Neurimmune AG • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for long COVID heart sufferers: drug combo trial launches
Disease control OngoingThis study tests whether a combination of anti-inflammatory and heart-protecting drugs can reduce symptoms and heart damage in people with Long COVID who have ongoing heart inflammation. About 279 adults with heart inflammation seen on MRI will receive either the drug combo or a …
Phase: PHASE3 • Sponsor: Valentina Puentmann • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Beating-Heart surgery offers hope for stiff heart muscle patients
Disease control OngoingThis study tests a new surgery done on a beating heart to help people with a type of thick heart muscle disease that causes symptoms like chest pain and shortness of breath. The surgery aims to remove a small part of the thickened heart muscle to improve blood flow and heart func…
Phase: NA • Sponsor: Xiang Wei • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody treatment aims to keep myeloma in check after transplant
Disease control OngoingThis phase 2 trial tests whether daratumumab, an antibody that targets cancer cells, can improve outcomes for people with multiple myeloma after they receive a stem cell transplant. The study involves 31 participants and is currently active but not recruiting. The main goal is to…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Gene therapy injection aims to repair failing hearts
Disease control OngoingThis study tests a one-time gene therapy called AB-1002, given directly into the heart arteries, for people with advanced heart failure (NYHA Class III). The goal is to see if it can improve heart function, reduce symptoms, and lower the risk of death or hospitalization. About 15…
Phase: PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a maintenance drug keep AL amyloidosis at bay?
Disease control OngoingThis phase 2 trial is testing whether the oral chemotherapy drug ixazomib can help control AL amyloidosis after initial treatment. Seventeen adults with the disease will take ixazomib along with low-dose dexamethasone to see if it delays organ progression or the need for more the…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Heart scan study sees if new drug clears sticky proteins
Disease control OngoingThis study looks at whether the drug eplontersen can reduce abnormal protein buildup in the heart for people with a condition called ATTR-CM. About 150 participants from a larger trial will get heart scans after 140 weeks of treatment. The goal is to see if the drug helps clear t…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene therapy trial for rare heart condition halted before it began
Disease control TerminatedThis study was designed to test a new gene therapy called ASP2016 for heart problems caused by Friedreich Ataxia, a rare genetic disease. The therapy aimed to deliver a healthy copy of the faulty gene to help the heart. However, the study was withdrawn before any participants wer…
Phase: PHASE1 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for rare heart disease: experimental drug tested for long-term safety
Disease control OngoingThis study tests the long-term safety of an experimental drug called NNC6019-0001 in people with transthyretin amyloid cardiomyopathy, a rare heart disease that can lead to heart failure. All 80 participants have already completed an earlier study and will receive the drug every …
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Weekly shot may help short kids grow – new study underway
Disease control OngoingThis study tests a new growth hormone medicine called somapacitan, given once a week, in 47 children who are very short due to being born small for gestational age, or having Turner syndrome, Noonan syndrome, or idiopathic short stature. The main goal is to see if it is safe and …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Gene therapy trial targets rare heart disease in 10 patients
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 for people with a heart condition called arrhythmogenic cardiomyopathy, caused by a change in the PKP2 gene. The study involves 10 adults who already have a defibrillator implanted. The main goal is to see if the treatment…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy for rare heart disease passes early safety check
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understan…
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy for gaucher disease: 5-year safety check begins
Disease control OngoingThis study follows 75 people with Gaucher disease type 1 who previously received FLT201 gene therapy. Researchers will monitor them for 5 years to see if the treatment remains safe and if its effects last. The goal is to understand whether a single dose can provide long-term dise…
Phase: PHASE1, PHASE2 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Pompe disease patients get continued enzyme therapy in Long-Term safety study
Disease control OngoingThis study follows 17 people with Pompe disease who have already taken part in earlier trials of avalglucosidase alfa (Nexviadyme). It aims to check the drug's long-term safety and effectiveness by giving it every two weeks as an IV infusion. The study will continue until the dru…
Phase: PHASE4 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for kids with pompe: enzyme combo trial underway
Disease control OngoingThis study tests a new treatment called cipaglucosidase alfa/miglustat in children (0 to under 18 years) with late-onset Pompe disease. The goal is to see if it is safe and how well it works. Participants either have never had enzyme therapy before or have been on it for at least…
Phase: PHASE3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Heart drug acoramidis tested for Long-Term safety in rare amyloidosis
Disease control OngoingThis study is checking the long-term safety of a drug called acoramidis in people with a rare heart condition called transthyretin amyloid cardiomyopathy. About 389 participants who finished a previous 30-month trial will take acoramidis twice daily for up to 5 years. Researchers…
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New chemo formula aims to boost transplant success in blood cancers
Disease control OngoingThis study tests a new, more stable version of the chemotherapy drug melphalan in people with multiple myeloma or AL amyloidosis who are getting a stem cell transplant. The goal is to find the best dose that reaches a target level in the body, while possibly causing fewer side ef…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Heart drug mavacamten under microscope: can it reshape damaged heart muscle?
Disease control OngoingThis phase 4 study tests the drug mavacamten in 63 adults with a type of heart muscle disease called obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve heart structure, measured by MRI, and ease symptoms like shortness of breath. Participants take…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill could ease severe asthma attacks
Disease control OngoingThis Phase 3 trial tests dexpramipexole, an oral tablet, as an add-on treatment for people with eosinophilic asthma that is not well controlled. About 600 participants aged 12 and older will receive either the drug or a placebo for 24 weeks. The study measures improvements in lun…
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Three extra minutes on an MRI could catch a deadly side effect of cancer treatment
Diagnosis OngoingThis study looks at whether adding just 3 minutes to a cardiac MRI can help doctors find heart inflammation (myocarditis) early in cancer patients on immunotherapy. Myocarditis is a rare but often deadly side effect of these drugs. The researchers will scan 200 patients who alrea…
Phase: NA • Sponsor: Centre Chirurgical Marie Lannelongue • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New ultrasound technique could sharpen heart arrhythmia diagnosis
Diagnosis ENROLLING_BY_INVITATIONThis study tests a new, non-invasive ultrasound method called electromechanical wave imaging (EWI) to see if it can more accurately locate and diagnose heart rhythm problems compared to standard tests. About 322 adults already scheduled for a heart procedure will get an EWI scan …
Phase: NA • Sponsor: Columbia University • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Can your apple watch spot hidden heart disease? mayo clinic study says AI might help.
Diagnosis OngoingThis study tests whether an artificial intelligence (AI) program can detect hypertrophic cardiomyopathy (HCM), a serious heart condition, using ECGs from standard machines, the Apple Watch, and the KardiaMobile device. Researchers will compare the AI's accuracy across these devic…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Simple blood test could catch hidden heart disease in seniors
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a way to find cardiac amyloidosis—a rare but serious heart condition—earlier in people aged 65 and older. Researchers in Turkey will screen 800 patients at family medicine clinics using simple blood tests and medical history. The goal is to see if this appro…
Sponsor: Kotyora Family Medicine Health Management and Education Association • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Super MRI could spot hidden heart damage
Diagnosis OngoingThis study tests whether a new, more powerful 7 Tesla MRI can better detect scarring and swelling in the heart muscle of people with cardiomyopathy. Researchers will scan 13 adults aged 20-70 to see if the higher-resolution images improve diagnosis. The goal is to see if this adv…
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Leg movement may predict heart risk in seniors
Diagnosis OngoingThis study explores whether a simple, non-invasive leg movement test can measure blood vessel health in older adults. Researchers will use ultrasound to track blood flow changes after a passive leg movement, comparing young healthy people and older patients undergoing heart tests…
Sponsor: VA Office of Research and Development • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
New test could predict falls in muscle disease patients
Diagnosis ENROLLING_BY_INVITATIONThis study aims to create a simple test battery to determine fall risk in people with neuromuscular disorders, such as muscular dystrophy or ALS. Researchers will assess 108 participants using several physical tests like walking, standing, and rising from a chair. The goal is to …
Sponsor: LMU Klinikum • Aim: Diagnosis
Last updated Jun 26, 2026 16:30 UTC
-
Massive study tests if daily pills can ward off cancer and heart attacks
Prevention OngoingThis large study tested whether taking daily vitamin D3 and omega-3 (fish oil) supplements can lower the risk of developing cancer, heart disease, or stroke. Over 25,000 healthy older adults (men 50+, women 55+) took the supplements or placebos for about 5 years. The goal is to s…
Phase: PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
Weight-Loss drug semaglutide tested as heart failure treatment
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether aggressive weight loss using semaglutide can improve symptoms in people with a specific type of heart failure linked to obesity. About 81 participants with a BMI of 30 or higher and heart failure with preserved ejection fraction will receive either sem…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Heart rehab gets personal: new program targets Women's sexual Well-Being
Symptom relief OngoingThis study tests a nurse-led education program designed to help women in cardiac rehab address sexual concerns after a heart event. Sixty-six women will be randomly assigned to either the program or usual care. The goal is to see if the program improves sexual function, mood, and…
Phase: NA • Sponsor: Hospital Universitario Virgen Macarena • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can a blood flow cuff boost heart rehab?
Symptom relief OngoingThis study tests whether adding blood flow restriction (BFR) to standard resistance training helps heart rehab patients get stronger and healthier. Twenty adults with stable heart disease will do exercises with and without a special cuff that limits blood flow to the arms and leg…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Pedal power: could stationary bike workouts protect hearts of young cancer survivors?
Symptom relief OngoingThis study looks at whether different levels of exercise can improve heart health in young adults who survived childhood cancer and were treated with a type of chemotherapy called anthracyclines, which can weaken the heart. Twenty survivors aged 18 to 39 will do either high-inten…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Can a diabetes drug boost heart function in non-diabetic patients?
Symptom relief OngoingThis study tests whether empagliflozin, a drug typically used for diabetes, can help people with hypertrophic cardiomyopathy (a thickened heart muscle) who do not have diabetes. About 250 adults will receive either the drug or a placebo daily for 12 months. The main goals are to …
Phase: PHASE3 • Sponsor: National Institute of Cardiology, Warsaw, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can slow breathing heal a broken heart? new study tests Device-Guided breathing
Symptom relief OngoingThis study tests whether a device that guides slow breathing can improve heart rate variability and quality of life in people who have had takotsubo syndrome (also known as broken heart syndrome). Ten patients with a history of takotsubo and ten healthy volunteers will use the RE…
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Could a simple nerve block cut opioid use after heart surgery?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a nerve block given before heart surgery can reduce pain and the need for opioid painkillers afterward. About 150 adults having heart surgery will receive either a long-acting or standard form of the numbing drug bupivacaine via ultrasound-guided injectio…
Phase: PHASE2, PHASE3 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
New heart drug aficamten aims to boost exercise and quality of life in HCM patients
Symptom relief OngoingThis phase 3 trial tests whether aficamten, an oral drug, can improve quality of life and exercise capacity in 500 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart condition that makes the heart muscle thick and stiff. Participants receive either afica…
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New program aims to ease burden on families of kids with rare diseases
Symptom relief ENROLLING_BY_INVITATIONThis study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …
Phase: NA • Sponsor: Children's National Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Hope for myotonic dystrophy: new drug shows promise in easing muscle stiffness Long-Term
Symptom relief ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of a drug called mexiletine PR for people with myotonic dystrophy types 1 and 2. The drug is taken once daily as a liquid to help reduce muscle stiffness (myotonia). The study includes 176 adults and teens who have alre…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Heart rehab gets a meaning boost: new study tests existential support
Symptom relief ENROLLING_BY_INVITATIONThis study tests a short program that helps heart patients and their families explore what gives life meaning during cardiac rehab. About 80 people in Denmark will try one of three formats: one-on-one, with a relative, or in a group. The goal is to see if this approach can reduce…
Phase: NA • Sponsor: University of Southern Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New drug aims to reduce pain and fatigue after stem cell transplant in older patients
Symptom relief OngoingThis study tests whether a drug called siltuximab can reduce symptoms like weakness, fatigue, nausea, and pain after a stem cell transplant in patients aged 60-75 with multiple myeloma or AL amyloidosis. The drug blocks a protein linked to inflammation, which may help patients re…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Could ditching Beta-Blockers boost heart Patients' exercise?
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether older adults with a heart condition called cardiac amyloidosis feel better and can exercise more when they stop taking beta-blockers. Twenty participants will each go through two periods: one on their beta-blocker and one off it. Researchers will measu…
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Can a simple blood test predict heart failure? cleveland clinic launches major study
Knowledge-focused OngoingThis study looks at how inflammation and oxidation (chemical reactions in the body) might damage the heart and lead to heart failure. Researchers are tracking over 1,200 healthy adults aged 40+ (or 18+ with a family history of heart failure) to see if waste products in blood or u…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Heart Patients' hidden danger: risky drug mixes under the microscope
Knowledge-focused OngoingThis study tracks 120 adults with heart disease and at least two other long-term illnesses to see how often dangerous drug interactions happen. Researchers check medications, including over-the-counter and herbal products, and follow participants for a year. The goal is to unders…
Sponsor: National Medical Research Center for Therapy and Preventive Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks rare genetic heart condition to guide future treatments
Knowledge-focused OngoingThis study follows about 35 people with dilated cardiomyopathy caused by a BAG3 gene mutation, a condition that weakens the heart muscle. Over three years, researchers will monitor heart function, symptoms, and quality of life using tests like imaging and blood work. The goal is …
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Weekly Check-Ins could boost patient satisfaction for chronic pain
Knowledge-focused TerminatedThis study looked at whether having more frequent contact with a clinician (at least once a week) improves satisfaction for people with long-lasting musculoskeletal conditions. Participants were split into two groups: one with standard contact and one with extra check-ins via tex…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can we predict who benefits from a heart device? new study aims to find out
Knowledge-focused OngoingThis study is for heart failure patients who do not have a specific heart rhythm pattern called left bundle branch block (non-LBBB). These patients often get a device called CRT-D, which combines a pacemaker and a defibrillator, but not everyone responds well. Researchers will fo…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study tracks how DM1 affects chinese patients over time
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 1000 Chinese patients with myotonic dystrophy type 1 (DM1) to understand how the disease affects multiple body systems and leads to disability. Researchers will collect health data and blood samples every 3 to 6 months for several years. The goal is to identify…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive genetic study aims to unlock secrets of rare metabolic diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study will collect and analyze genetic data from 1000 people with suspected inherited metabolic diseases, including conditions like epilepsy and mitochondrial disorders. Researchers at Karolinska University Hospital aim to improve diagnosis by using advanced genetic testing …
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Brain scans reveal diabetes link to cognitive decline in rare disease
Knowledge-focused OngoingThis study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have mor…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
German health data reveals how rare heart condition affects patients
Knowledge-focused OngoingThis study uses anonymous health insurance records from Germany to learn more about a rare heart condition called ATTR-CM, where abnormal protein builds up in the heart. Researchers will look at survival rates, hospital visits, and how common the disease is. No new treatments are…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Heart patients face bleeding and clot risks after joint surgery – new study investigates
Knowledge-focused OngoingThis study tracks over 1,700 heart patients who had hip or knee replacement surgery. Researchers want to see how often bleeding or blood clots happen in the months after surgery. The goal is to find better ways to prevent these complications.
Sponsor: I.M. Sechenov First Moscow State Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can a special clinic get workers back on the job faster? norway launches massive study.
Knowledge-focused OngoingThis study tests whether a Norwegian clinic (NSAC) helps people with common mental health issues or muscle pain return to work sooner. 2500 adults are split into three groups: one gets treatment quickly, one waits 10-14 weeks, and one gets a basic check-up. Researchers will track…
Phase: NA • Sponsor: Nordlandssykehuset HF • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Heart clinic gene test could save families from sudden death
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to make genetic testing for inherited heart muscle disease available directly in heart failure clinics, instead of requiring a separate referral to a genetics specialist that can take years. Researchers will train heart doctors to order a simple blood or saliva te…
Phase: NA • Sponsor: Thomas Roston • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New study tracks heart inflammation in teens after pfizer vaccine
Knowledge-focused OngoingThis study follows 319 people under 21 who developed heart inflammation (myocarditis or pericarditis) within 21 days of receiving the Comirnaty (Pfizer) COVID-19 vaccine. Researchers will monitor their heart function with imaging tests for up to 5 years to see if there are lastin…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Real-World HCM drug use under the microscope
Knowledge-focused OngoingThis study follows 331 adults with hypertrophic cardiomyopathy (HCM) to see how they are treated in everyday medical practice, especially with the drug mavacamten. Researchers will collect data on diagnosis, symptoms, treatments, and outcomes over time. The goal is to understand …
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can we tell diabetic heart disease apart from other heart conditions?
Knowledge-focused OngoingThis study looks at over 1,200 adults with type 2 diabetes and heart muscle problems to see if diabetic cardiomyopathy is a unique condition. Researchers will use detailed medical tests, imaging, and biological data to find patterns. The goal is to better understand and diagnose …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
200,000 heart patients enrolled in massive 5-Year fitness tracking study
Knowledge-focused ENROLLING_BY_INVITATIONThis study will observe 200,000 Chinese adults with heart disease to see how their heart and lung function changes over 5 years. Participants will take a special exercise test to measure their fitness. Researchers hope to find better ways to predict future heart problems like hea…
Sponsor: Guangdong Provincial People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New study aims to unravel mysterious heart condition
Knowledge-focused OngoingThis study looks at 600 adults with non-compaction cardiomyopathy, a rare heart muscle condition that can lead to heart failure, stroke, or dangerous heart rhythms. Researchers will use heart scans, genetic tests, and health records to find better ways to predict who is at highes…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Severe asthma drug may boost daily steps, study hopes
Knowledge-focused OngoingThis study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Heart scans after COVID shot: new study aims to uncover hidden risks
Knowledge-focused OngoingThis study looks at 57 people who received a COVID-19 vaccine to understand why some develop heart injury or myocarditis. Researchers use advanced heart scans (PET/MRI) and blood tests to find early warning signs. The goal is to better identify those at risk and improve follow-up…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Heart MRI could spot hidden disease in families before symptoms appear
Knowledge-focused OngoingThis study uses advanced heart MRI scans to look for the earliest signs of dilated cardiomyopathy (a weakened heart muscle) in close relatives of people already diagnosed. Researchers will follow 650 family members over time to see how genetic factors relate to heart changes. The…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Smartwatch ECG tested for heart risk in childhood cancer survivors
Knowledge-focused OngoingThis study looks at whether a smartwatch ECG can predict heart muscle disease (cardiomyopathy) in adult survivors of childhood cancer as well as a standard clinic ECG does. About 1,300 survivors will have both a standard 12-lead ECG and a 30-second Apple Smartwatch ECG. The goal …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study digs into how mepolizumab changes nose bacteria and genes in asthma patients
Knowledge-focused OngoingThis study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…
Sponsor: National and Kapodistrian University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can a new heart drug improve blood flow in thick heart muscle?
Knowledge-focused OngoingThis study looks at whether a new type of heart medication, called a cardiac myosin inhibitor, can improve blood flow in the small blood vessels of the heart in people with hypertrophic cardiomyopathy (HCM). Researchers will use special ultrasound imaging to measure blood flow be…
Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Massive heart study aims to unlock secrets of cardiovascular disease
Knowledge-focused OngoingThis study is a large registry that collects medical data and tissue samples from 30,000 people with heart disease and healthy volunteers. Researchers will analyze this information to better understand risk factors, treatments, and outcomes for various heart conditions. The goal …
Sponsor: Intermountain Health Care, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Pompe disease study aims to clear path for gene therapy
Knowledge-focused OngoingThis study looks at people with late-onset Pompe disease to measure antibodies against a virus used in gene therapy and against the standard enzyme replacement therapy. It also checks for biomarkers in blood and urine. About 119 teenagers and adults will give samples over 2 years…
Phase: NA • Sponsor: Astellas Gene Therapies • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New heart study aims to cut unnecessary pacemaker implants by half
Knowledge-focused OngoingThis study tests whether using an ultrasound measure of heart muscle coordination (mechanical dyssynchrony) can better select heart failure patients for cardiac resynchronization therapy (CRT) than current guidelines. About 500 patients will receive a CRT device, but pacing will …
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Athletes' hearts under watch: new study tracks rhythm risks after myocarditis
Knowledge-focused OngoingThis study follows 50 athletes who had acute myocarditis (heart muscle inflammation) to see how often they develop dangerous heart rhythms. Participants wear a portable ECG monitor and do a treadmill stress test at 3 months and 1 year after their illness. The goal is to learn mor…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Pacemaker study aims to predict and prevent heart weakening
Knowledge-focused OngoingThis study is observing 4,500 people who need pacemakers or similar heart devices. The goal is to create a tool that predicts who is at risk of developing a weakened heart from the device itself. By identifying high-risk patients early, doctors can choose better pacing methods to…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Heart disease study aims to unlock genetic secrets of dilated cardiomyopathy
Knowledge-focused OngoingThis study follows 2000 people with dilated cardiomyopathy (a weakened, enlarged heart) over several years to learn how genetics and heart scarring affect the disease. Participants give blood for genetic testing and have heart MRI scans. The goal is to improve diagnosis and pave …
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New study aims to uncover why people with muscle disease fall
Knowledge-focused OngoingThis study measures how often people with myotonic dystrophy type 1 fall and what factors affect their balance. Researchers will also assess fear of falling and leg muscle strength. The goal is to better understand fall risk in this condition.
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Sepsis heart damage: new study aims to unravel mysteries
Knowledge-focused OngoingThis study looks at how sepsis, a severe infection, can cause heart problems in intensive care patients. Researchers will collect data, blood samples, and heart ultrasound images from 330 adults with septic shock. The goal is to find patterns that help doctors better diagnose and…
Sponsor: Linkoeping University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Massive PT study mines 4 million records to find what works best
Knowledge-focused OngoingThis study looks back at the medical records of about 4 million people who had physical or occupational therapy for muscle and joint problems. Researchers want to see if different ways of giving therapy lead to different results. No new treatments are tested—the goal is to learn …
Sponsor: ATI Holdings, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
PET scans may outshine ejection fraction in predicting sudden cardiac death
Knowledge-focused OngoingThis study looks at whether a special PET scan can help doctors better predict sudden cardiac arrest in people with heart failure and blocked arteries. About 300 participants who already have a defibrillator will be followed to see if heart nerve damage, heart size, or blood mark…
Sponsor: State University of New York at Buffalo • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Phone app vs. doctor: can a mobile tool catch infections after surgery?
Knowledge-focused TerminatedThis study aimed to see if a mobile monitoring tool could accurately identify surgical site infections (SSIs) in orthopedic surgery patients, compared to the usual manual review. The study was withdrawn before enrolling any participants, so no results are available. It was design…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New registry tracks how ATTR-CM patients are treated in daily practice
Knowledge-focused OngoingThis study is a disease registry that collects information from routine medical care of about 350 adults diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) in Taiwan, Hong Kong, and Malaysia. Researchers will look at patient characteristics, treatments received, and ho…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Heart rhythm secrets in thick heart muscle disease revealed
Knowledge-focused OngoingThis study looks at heart rhythm problems in people with hypertrophic cardiomyopathy, a condition where the heart muscle is thicker than normal. Researchers want to see how often new rhythm issues like atrial fibrillation happen, and whether sleep apnea plays a role. About 260 ad…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New digital tool aims to tame uncontrolled asthma in GP practices
Knowledge-focused OngoingThis study tests a digital tool called AsthmaOptimiser that helps doctors assess asthma control and find ways to improve treatment during a single visit. About 746 adults with asthma who have had recent flare-ups will take part. The goal is to see if the tool can identify better …
Phase: NA • Sponsor: General Practitioners Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
10,000 heart patients enrolled in quest to predict sudden death
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study will enroll 10,000 adults with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. Researchers will combine genetic tests, advanced heart imaging, and blood markers to create better tools for early diagnosis and to predict risk…
Sponsor: Minjie Lu • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
ICU stay throws body clocks out of sync, new study reveals
Knowledge-focused OngoingThis study looks at how being in a hospital intensive care unit (ICU) after heart surgery affects your body's natural sleep-wake cycle. Researchers will track sleep patterns and thinking ability in 15 adults to see if disrupted rhythms slow down recovery. The goal is to understan…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
AI takes on heart scans: can it match expert radiologists?
Knowledge-focused OngoingThis study is testing whether an artificial intelligence (AI) model can automatically write reports for cardiac MRI scans as accurately as experienced radiologists. Researchers will compare AI-generated reports with those written by experts using 20,000 patient scans. The goal is…
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Family doctors train to spot heart problems with ultrasound
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether a special training program can help family doctors use focused heart ultrasound (FoCUS) to accurately detect common heart conditions like heart failure and valve disease. About 500 patients will get both a family doctor's FoCUS and a cardiologist's ful…
Sponsor: Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists build heart cells in a dish to unravel genetic heart disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood or skin samples from 100 adults with inherited heart rhythm disorders (like Long QT Syndrome or Brugada Syndrome) and healthy volunteers. Researchers will turn these samples into stem cells and then into heart cells to study how these diseases work and t…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Proteomics may unlock key clues to mepolizumab success in rare lung disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Heart MRI study aims to spot who is at risk from myocarditis
Knowledge-focused ENROLLING_BY_INVITATIONThis study will use advanced cardiac MRI scans to look at different patterns of heart inflammation in 5,000 people with myocarditis or inflammatory cardiomyopathy. The goal is to see if certain MRI findings can better predict who will have serious heart problems later, like heart…
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Bronx database sheds light on underdiagnosed heart condition in women and minorities
Knowledge-focused OngoingThis study creates a database of 476 patients in the Bronx who were tested for transthyretin amyloid cardiomyopathy (ATTR-CM), a serious and often missed heart condition. Researchers collected health records, imaging results, and outcomes like hospitalizations and deaths. The goa…
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Heart study seeks to uncover why some Thick-Heart patients fare worse
Knowledge-focused OngoingThis observational study looks at 165 people with two different types of heart muscle thickening: syndromic/metabolic cardiomyopathy (SMCs) and hypertrophic cardiomyopathy (HCM). Researchers want to see if SMCs patients have worse heart outcomes like death or heart failure, and w…
Sponsor: China National Center for Cardiovascular Diseases • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
8,000-Patient MRI study aims to unlock secrets of heart disease
Knowledge-focused OngoingThis study uses advanced MRI techniques to measure changes in heart muscle tissue in 8,000 adults with heart failure, heart muscle disease, inflammation, coronary artery disease, or chronic kidney disease. The goal is to see if these measurements can help doctors better diagnose …
Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Silent tumors may still harm the heart, new study warns
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at people with rare adrenal tumors (pheochromocytomas and paragangliomas) that do not produce excess hormones. Researchers want to see if these 'silent' tumors still cause heart problems, blood pressure changes, or metabolic issues like diabetes and high choleste…
Sponsor: Laikο General Hospital, Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Massive gene hunt launched for mysterious mitochondrial diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to discover new genetic mutations that cause mitochondrial disorders by analyzing tissue samples from up to 6,900 participants. It includes people with suspected or known mitochondrial diseases, such as MELAS or Leigh's Disease, who lack a genetic diagnosis. The r…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New SPECT method could reveal hidden heart issues in amyloidosis patients
Knowledge-focused OngoingThis study looks at 50 people with TTR amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. Researchers want to see if a special SPECT scan can measure blood flow in the heart's tiny vessels, which may be impaired even without blocked arteries. Parti…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Study on faster recovery after heart procedure pulled before starting
Knowledge-focused TerminatedThis study aimed to see if using a special pad along with a standard closure device could help patients get out of bed sooner after a heart catheterization. It was planned for adults having the procedure through the groin. However, the study was withdrawn before any participants …
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New registry aims to uncover heart disease secrets in russia
Knowledge-focused ENROLLING_BY_INVITATIONThis study is creating a large database of 1400 adults and children with hypertrophic cardiomyopathy (HCM) in Russia. Researchers will track their health over time to learn how the disease progresses and affects daily life. The goal is to improve diagnosis and care for HCM patien…
Sponsor: Central State Medical Academy • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Global heart registry tracks ablation success
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a large international registry that collects information from patients who have a heart ablation procedure for ventricular tachycardia or premature ventricular contractions. The goal is to track how well the procedure works and any complications, helping doctors imp…
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Heart scans reveal hidden protein buildup in rare disease
Knowledge-focused OngoingThis study uses MRI scans to measure amyloid protein buildup in the hearts of up to 150 people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Participants are already enrolled in a larger treatment trial. The goal is to see how amyloid levels change over time, not …
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Heart scans aim to uncover hidden damage in duchenne patients
Knowledge-focused TerminatedThis study was designed to track heart muscle changes in people with Duchenne muscular dystrophy using two cardiac MRIs taken two years apart, along with blood tests for heart failure markers. It planned to enroll participants aged 6 and older with a confirmed genetic diagnosis. …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New study aims to find gentler radiation for breast cancer Patients' hearts
Knowledge-focused OngoingThis study compares two types of radiation therapy for left-sided breast cancer: proton beam therapy and conventional photon therapy. The goal is to see which one causes fewer changes to the heart, measured by MRI scans. About 60 adults with non-metastatic breast cancer will part…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Scientists watch LGMD progress in 205 patients over years
Knowledge-focused OngoingThis study follows 205 people with four types of limb-girdle muscular dystrophy (LGMD) to understand how the disease changes over time. Participants will have their muscle strength, movement, and breathing tested regularly for up to 5 years. No treatment is given; the goal is to …
Sponsor: Sarepta Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New registry aims to uncover hidden risks for pregnant women with heart disease
Knowledge-focused OngoingThis registry follows 75 pregnant women with heart disease to better understand the risks and outcomes for both mother and baby. Researchers will track health data for one year and check vital status at five years. The goal is to fill knowledge gaps and improve future care for th…
Sponsor: Saint Luke's Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
New study aims to predict swallowing trouble after heart surgery
Knowledge-focused OngoingThis study follows 347 heart surgery patients to understand why some develop swallowing problems (dysphagia). Researchers will use special camera tests to watch how patients swallow and look for risk factors. The goal is to create simple tools that doctors can use at the bedside …
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New study aims to map rare muscle disease progression
Knowledge-focused TerminatedThis study was designed to track the natural course of gamma-sarcoglycanopathy (LGMDR5), a rare muscle-weakening disease, over two years. Researchers planned to measure changes in muscle strength, walking ability, and daily function in patients aged 6 to 35. The goal was to bette…
Sponsor: Atamyo Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
10,000 heart scans could unlock secrets of cardiovascular disease
Knowledge-focused OngoingThis study is following 10,000 adults who are having a heart MRI for medical reasons. Researchers want to see if the MRI results can help predict who will have heart problems in the future, like heart attacks or heart failure. The goal is to better understand how MRI scans can gu…
Sponsor: Manchester University NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New registry to monitor growth hormone treatment in kids with rare condition
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on growth, side effects, and quality of life over time. No new treatment is being tested—the g…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New study tracks early signs of pompe disease in newborns
Knowledge-focused OngoingThis study follows 20 newborns and children diagnosed with late-onset Pompe disease through newborn screening. Researchers will track their health for up to 4.5 years to document early muscle and joint symptoms, biomarkers, and quality of life. The goal is to learn when to start …
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC